10-year trends in statin utilization in Taiwan: A retrospective study using Taiwan's National Health Insurance Research Database

Hsing Chun Hsieh, Jason C. Hsu, Christine Y. Lu

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Objective Statins have been commonly used to treat patients with hypercholesterolaemia and to prevent cardiovascular disease (CVD) worldwide. This study examined trends in use of statins in Taiwan from 2002 to 2011. Design This is a retrospective observational study focusing on the utilisation of statins. Setting The monthly claims data for statins between 2002 and 2011 were retrieved from Taiwan's National Health Insurance Research Database. Main outcome measures We calculated the yearly prescription rate per new user for each statin. Products were classified as high-intensity/moderate-intensity/low-intensity statins by type of statin and dosage. Users were also classified based on disease histories. Results The number of statin users increased from 10 299 (∼1.4% of adults) in 2002 to 50 687 (∼6.3% of adults) in 2011. Atorvastatin was the most commonly used agent (28.4%-36.7%) during the study period. After 2007, simvastatin ranked second with 21.7% market share, followed by rosuvastatin, a newer agent that exhibited a substantial growth in prescription rates (3.4% in 2005 and 19.5% in 2011). In 2011, 94.0% of new statin users used statin monotherapies, and 6.0% used combination therapies. Use of moderate-intensity statins increased from 49.0% in 2002 to 71.0% in 2011, while high-intensity statins remained low. Patients with history of coronary events or cerebrovascular events were more likely to be prescribed higher intensity statins compared with those without. Prescribing of higher intensity statins was not greater among people with diabetes compared with those without during 2007-2011. Selection of statins did not differ between people with versus without history of myopathy or liver injury. Conclusion Atorvastatin was the most commonly used statin in Taiwan during 2002-2011. While patients with history of CVD were more likely to be prescribed higher intensity statins compared with those without, this difference was not found comparing those with and without diabetes.

Original languageEnglish
Article numbere014150
JournalBMJ open
Volume7
Issue number5
DOIs
Publication statusPublished - 2017 May 1

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
National Health Programs
Taiwan
Retrospective Studies
Databases
Research
Prescriptions
Cardiovascular Diseases
Simvastatin

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

@article{980b918b5d2a4c9489096b008b434cbe,
title = "10-year trends in statin utilization in Taiwan: A retrospective study using Taiwan's National Health Insurance Research Database",
abstract = "Objective Statins have been commonly used to treat patients with hypercholesterolaemia and to prevent cardiovascular disease (CVD) worldwide. This study examined trends in use of statins in Taiwan from 2002 to 2011. Design This is a retrospective observational study focusing on the utilisation of statins. Setting The monthly claims data for statins between 2002 and 2011 were retrieved from Taiwan's National Health Insurance Research Database. Main outcome measures We calculated the yearly prescription rate per new user for each statin. Products were classified as high-intensity/moderate-intensity/low-intensity statins by type of statin and dosage. Users were also classified based on disease histories. Results The number of statin users increased from 10 299 (∼1.4{\%} of adults) in 2002 to 50 687 (∼6.3{\%} of adults) in 2011. Atorvastatin was the most commonly used agent (28.4{\%}-36.7{\%}) during the study period. After 2007, simvastatin ranked second with 21.7{\%} market share, followed by rosuvastatin, a newer agent that exhibited a substantial growth in prescription rates (3.4{\%} in 2005 and 19.5{\%} in 2011). In 2011, 94.0{\%} of new statin users used statin monotherapies, and 6.0{\%} used combination therapies. Use of moderate-intensity statins increased from 49.0{\%} in 2002 to 71.0{\%} in 2011, while high-intensity statins remained low. Patients with history of coronary events or cerebrovascular events were more likely to be prescribed higher intensity statins compared with those without. Prescribing of higher intensity statins was not greater among people with diabetes compared with those without during 2007-2011. Selection of statins did not differ between people with versus without history of myopathy or liver injury. Conclusion Atorvastatin was the most commonly used statin in Taiwan during 2002-2011. While patients with history of CVD were more likely to be prescribed higher intensity statins compared with those without, this difference was not found comparing those with and without diabetes.",
author = "Hsieh, {Hsing Chun} and Hsu, {Jason C.} and Lu, {Christine Y.}",
year = "2017",
month = "5",
day = "1",
doi = "10.1136/bmjopen-2016-014150",
language = "English",
volume = "7",
journal = "BMJ Open",
issn = "2044-6055",
publisher = "BMJ Publishing Group",
number = "5",

}

10-year trends in statin utilization in Taiwan : A retrospective study using Taiwan's National Health Insurance Research Database. / Hsieh, Hsing Chun; Hsu, Jason C.; Lu, Christine Y.

In: BMJ open, Vol. 7, No. 5, e014150, 01.05.2017.

Research output: Contribution to journalArticle

TY - JOUR

T1 - 10-year trends in statin utilization in Taiwan

T2 - A retrospective study using Taiwan's National Health Insurance Research Database

AU - Hsieh, Hsing Chun

AU - Hsu, Jason C.

AU - Lu, Christine Y.

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Objective Statins have been commonly used to treat patients with hypercholesterolaemia and to prevent cardiovascular disease (CVD) worldwide. This study examined trends in use of statins in Taiwan from 2002 to 2011. Design This is a retrospective observational study focusing on the utilisation of statins. Setting The monthly claims data for statins between 2002 and 2011 were retrieved from Taiwan's National Health Insurance Research Database. Main outcome measures We calculated the yearly prescription rate per new user for each statin. Products were classified as high-intensity/moderate-intensity/low-intensity statins by type of statin and dosage. Users were also classified based on disease histories. Results The number of statin users increased from 10 299 (∼1.4% of adults) in 2002 to 50 687 (∼6.3% of adults) in 2011. Atorvastatin was the most commonly used agent (28.4%-36.7%) during the study period. After 2007, simvastatin ranked second with 21.7% market share, followed by rosuvastatin, a newer agent that exhibited a substantial growth in prescription rates (3.4% in 2005 and 19.5% in 2011). In 2011, 94.0% of new statin users used statin monotherapies, and 6.0% used combination therapies. Use of moderate-intensity statins increased from 49.0% in 2002 to 71.0% in 2011, while high-intensity statins remained low. Patients with history of coronary events or cerebrovascular events were more likely to be prescribed higher intensity statins compared with those without. Prescribing of higher intensity statins was not greater among people with diabetes compared with those without during 2007-2011. Selection of statins did not differ between people with versus without history of myopathy or liver injury. Conclusion Atorvastatin was the most commonly used statin in Taiwan during 2002-2011. While patients with history of CVD were more likely to be prescribed higher intensity statins compared with those without, this difference was not found comparing those with and without diabetes.

AB - Objective Statins have been commonly used to treat patients with hypercholesterolaemia and to prevent cardiovascular disease (CVD) worldwide. This study examined trends in use of statins in Taiwan from 2002 to 2011. Design This is a retrospective observational study focusing on the utilisation of statins. Setting The monthly claims data for statins between 2002 and 2011 were retrieved from Taiwan's National Health Insurance Research Database. Main outcome measures We calculated the yearly prescription rate per new user for each statin. Products were classified as high-intensity/moderate-intensity/low-intensity statins by type of statin and dosage. Users were also classified based on disease histories. Results The number of statin users increased from 10 299 (∼1.4% of adults) in 2002 to 50 687 (∼6.3% of adults) in 2011. Atorvastatin was the most commonly used agent (28.4%-36.7%) during the study period. After 2007, simvastatin ranked second with 21.7% market share, followed by rosuvastatin, a newer agent that exhibited a substantial growth in prescription rates (3.4% in 2005 and 19.5% in 2011). In 2011, 94.0% of new statin users used statin monotherapies, and 6.0% used combination therapies. Use of moderate-intensity statins increased from 49.0% in 2002 to 71.0% in 2011, while high-intensity statins remained low. Patients with history of coronary events or cerebrovascular events were more likely to be prescribed higher intensity statins compared with those without. Prescribing of higher intensity statins was not greater among people with diabetes compared with those without during 2007-2011. Selection of statins did not differ between people with versus without history of myopathy or liver injury. Conclusion Atorvastatin was the most commonly used statin in Taiwan during 2002-2011. While patients with history of CVD were more likely to be prescribed higher intensity statins compared with those without, this difference was not found comparing those with and without diabetes.

UR - http://www.scopus.com/inward/record.url?scp=85019629565&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019629565&partnerID=8YFLogxK

U2 - 10.1136/bmjopen-2016-014150

DO - 10.1136/bmjopen-2016-014150

M3 - Article

C2 - 28515189

AN - SCOPUS:85019629565

VL - 7

JO - BMJ Open

JF - BMJ Open

SN - 2044-6055

IS - 5

M1 - e014150

ER -